Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

ACTIV-3/TICO (tixa), 2022 NCT04501978

cilgavimab and tixagevimab (Evusheld) (n=710) vs. placebo (n=707)

randomized controlled trial   some concerns about risk of bias

Studied treatment

intravenous tixagevimab 300 mg/cilgavimab 300 mg

Control treatment

placebo

in addition to remdesivir and other standard care

Patients

COVID 19 hospitalized

Method

double-blind

81 sites on four continents

efficacy and safety analyses were performed in the modified intention-to-treat population, defined as participants who received a complete or partial infusion of tixagevimab/cilgavimab or placebo

Remark